Status:
UNKNOWN
Genomic Study of Relapse Esophageal Cancer After Radiotherapy
Lead Sponsor:
Fudan University
Collaborating Sponsors:
M.D. Anderson Cancer Center
Nantong University
Conditions:
Gene Mutation-Related Cancer
Esophageal Cancer
Eligibility:
All Genders
Brief Summary
Radiotherapy plays an important role in multidisciplinary treatment of esophageal cancer. However, about half patients received radiotherapy occurred relapse. Once relapse occurred, there is no better...
Detailed Description
Tumor tissue of patients received radiotherapy with diagnosis of recurrence between Jan 1, 2010 and Dec 1, 2020 were collected retrospectively. Recurrence tumor tissue is collected between Dec 31, 202...
Eligibility Criteria
Inclusion
- pathologic diagnosis is squamous cell carcinoma before radiotherapy;
- pathologic diagnosis is squamous cell carcinoma after radiotherapy;
- received radiotherapy
- clinical symptoms including dysphagia, feeding obstruction, etc
- image evidence showed disease progression
- the period of recurrence was within 2 years after radiotherapy
Exclusion
- pathologic diagnosis is not squamous cell carcinoma before radiotherapy;
- pathologic diagnosis is not squamous cell carcinoma after radiotherapy
- not received radiotherapy
- the period of recurrence was more than 2 years after radiotherapy
- the period of no recurrence was within 3 years after radiotherapy
Key Trial Info
Start Date :
September 14 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04694391
Start Date
September 14 2012
End Date
December 31 2022
Last Update
January 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan university shanghai cancer center
Shanghai, China, 200032